RxDoctor Payments Data

Amber Hetrick, MD

Neurology · Fort Wayne, INNPI 1508270810

Payments from drug & device makers

$1,277in general payments, 2019–2025

Across 57 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$594
  • Vanda Pharmaceuticals Inc.$459
  • Pfizer$115
  • Novartis$30
  • Supernus Pharmaceuticals, Inc.$22
  • Biogen$17
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$1,26599%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,277 in reported general payments places this provider in the 40th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$49,116
Medicare patients
283
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod11$174,416
Nurtec OdtRimegepant Sulfate90$102,859
Aimovig AutoinjectorErenumab-Aooe65$84,414
UbrelvyUbrogepant80$78,346
QuliptaAtogepant49$66,174
Emgality PenGalcanezumab-Gnlm13$24,316
XcopriCenobamate17$21,968
Sumatriptan Succinate95$15,581
Tegretol XrCarbamazepine13$8,504
ReyvowLasmiditan Succinate11$8,018
Lacosamide32$7,632
NayzilamMidazolam11$7,042
Carbidopa-LevodopaCarbidopa/Levodopa172$4,274
RivastigmineRivastigmine Tartrate55$4,105
Dimethyl Fumarate14$3,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$30$174,41611 claims
AbbVieUbrelvy, Qulipta$594$144,519129 claims
PfizerNurtec Odt$115$102,85990 claims
Lilly USA, LLCReyvow$13$8,01811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 308 neurology providers in Indiana.

Other neurology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →